Literature DB >> 24862874

Evidence of an environmental effect on survival in ALS.

Noa Keren1, Kirsten M Scott, Miho Tsuda, Jessica Barnwell, Jonathan A Knibb, Cathy M Ellis, P Nigel Leigh, Christopher E Shaw, Ammar Al-Chalabi.   

Abstract

Amyotrophic lateral sclerosis (ALS, motor neuron disease) is a neurodegenerative disorder of motor neurons leading to paralysis and eventual death by respiratory failure. Median survival is 2-3 years. Susceptibility genes, environmental triggers and disease related prognostic factors have been established, but environmental effects on survival are yet to be investigated. We analysed survival in the South-East England ALS register (SEALS register). Kaplan-Meier and Cox regression analyses were used to investigate survival in London, coastal and rural areas according to postcode at diagnosis. Results showed that there were 933 cases of ALS identified in the catchment area during the study period (1994-January 2012). Cox regression demonstrated a highly significant model for survival with significant protective variables: coastal residency, riluzole use and younger age at onset. Significantly worse survival was associated with London residency, older age as well as definite and probable El Escorial classifications. In conclusion, these findings suggest the possibility of an environmental effect on survival in ALS.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; cluster; motor neuron disease; population study; survival

Mesh:

Year:  2014        PMID: 24862874     DOI: 10.3109/21678421.2014.911326

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  6 in total

1.  Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

2. 

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

3.  Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study.

Authors:  Federica Edith Pisa; Giancarlo Logroscino; Paolo Giacomelli Battiston; Fabio Barbone
Journal:  BMC Pulm Med       Date:  2016-11-03       Impact factor: 3.317

Review 4.  Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma.

Authors:  Reka P Toth; Julie D Atkin
Journal:  Front Immunol       Date:  2018-05-23       Impact factor: 7.561

5.  Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients.

Authors:  Xueping Chen; Qian-Qian Wei; Yongping Chen; Bei Cao; RuWei Ou; Yanbing Hou; Xiaoqin Yuan; Lingyu Zhang; Hui Liu; Huifang Shang
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

6.  Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity.

Authors:  Uros Klickovic; Luca Zampedri; Christopher D J Sinclair; Stephen J Wastling; Karin Trimmel; Robin S Howard; Andrea Malaspina; Nikhil Sharma; Katie Sidle; Ahmed Emira; Sachit Shah; Tarek A Yousry; Michael G Hanna; Linda Greensmith; Jasper M Morrow; John S Thornton; Pietro Fratta
Journal:  Neurology       Date:  2019-08-07       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.